The Use of Methyldopa in Schizophrenia: A Review and Comparative Study
Abstract
Since methvldopa has been classified as a central nervous system depressant that produces tranquilization and reversible extrapyramidal symptoms, as well as reducing central amines, it has been suggested that it might have an antipsychotic potential. The authors' study showed a statistically significant deterioration in patients treated with methyldopa as compared with those treated with methotrimeprazine; however, five patients showed some improvement on methyldopa. It is suggested that methyldopa's lack of general antipsychotic activity is related to the reduced dopamine concentration in the brain instead of an increased turnover rate, which is characteristic of more effective neuroleptic drugs.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).